Stockscreener 앱 받기
3.5242
3.05%
0.1042
시간 외 거래:
3.52
-0.0042
-0.12%
전일 마감가:
$3.42
열려 있는:
$3.53
하루 거래량:
24,209
Relative Volume:
2.90
시가총액:
$175.88M
수익:
-
순이익/손실:
-
주가수익비율:
-4.8007
EPS:
-0.7341
순현금흐름:
-
1주 성능:
+3.35%
1개월 성능:
+1.56%
6개월 성능:
-30.39%
1년 성능:
-1.01%
1일 변동 폭
$3.392
$3.54
1주일 범위
$3.322
$3.68
52주 변동 폭
$3.11
$6.4229
Genfit Adr Stock (GNFT) Company Profile
GNFT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
3.5242 | 175.88M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-12-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | 업그레이드 | Stifel | Hold → Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Underperform |
| 2020-05-13 | 다운그레이드 | Kepler | Buy → Reduce |
| 2020-05-12 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-05-12 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | 재확인 | B. Riley FBR | Buy |
| 2019-06-25 | 개시 | Stifel | Hold |
| 2019-04-24 | 개시 | SVB Leerink | Outperform |
| 2019-04-22 | 개시 | Barclays | Overweight |
모두보기
Genfit Adr 주식(GNFT)의 최신 뉴스
European Equities Traded in the US as American Depositary Receipts Tread Water in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Down for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Climb Higher in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Surge Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView
GENFIT annonce les résultats préliminaires de l’Offre de Rachat proposée aux porteurs d’OCEANEs 2025 et la Convocation de l’assemblée générale des porteurs d’OCEANEs 2025 - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Open Week Slightly Higher - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Move Higher in Tuesday Trading - MSN
GENFIT: Historic Milestone Achieved with U.S. FDA - GlobeNewswire
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen und GENFIT schließen im Rahmen einer langfristigen globalen Partnerschaft eine exklusive Lizenzvereinbarung für Elafibranor ab, ein Phase-III-Asset, das für die Behandlung von primärer biliärer Cholangitis geprüft wird - Business Wire
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO - Yahoo Finance
Genfit Adr (GNFT) 재무 분석
Genfit Adr (GNFT)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
3.89%
0.13%
자본화:
|
볼륨(24시간):